Petar Petrov

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Does the Strengths and Difficulties Questionnaire – self report yield invariant measurements across different nations? Data from the International Child Mental Health Study Group

Dejan Stevanović, Róbert Urbán, Olayinka Atilola et al. · Epidemiology and Psychiatric Sciences · 2014 · 70 citations · Full text

Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study)

Saulius Cicėnas, Sarayut Lucien Geater, Petar Petrov et al. · Lung Cancer · 2016 · 57 citations · Full text

UCLA PTSD reaction index for DSM-5 (PTSD-RI-5): a psychometric study of adolescents sampled from communities in eleven countries

Dejan Stevanović, Duško Stupar, Panos Vostanis et al. · European journal of psychotraumatology · 2019 · 56 citations · Full text

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)

Suresh S. Ramalingam, Jeffrey Crawford, Alex Y. Chang et al. · Annals of Oncology · 2013 · 55 citations

Antifibrotic Therapy, Fortis-m Trial, Medicine +9